ProCE Banner Activity

Selecting Therapy for AML Without Predictive Biomarkers or Therapeutically Actionable Genomic or Molecular Alterations

Slideset Download
Download these slides from a live webinar for the most recent data on selecting AML therapy for patients without predictive biomarkers or molecular alterations.

Released: July 28, 2022

Expiration: July 27, 2023

Share

Faculty

Naval G. Daver

Naval G. Daver, MD

Associate Professor
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas

Provided by

Provided by National Comprehensive Cancer Network.
ProCE Banner

Supporters

Supported by educational grants from

AbbVie Inc.

Genentech, a member of the Roche Group

Jazz Pharmaceuticals, Inc.

Faculty Disclosure

Primary Author

Naval G. Daver, MD

Associate Professor
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas

Naval Daver, MD: consultant/advisor/speaker: AbbVie, Agios, Astellas, Amgen, Arog, Bristol-Myers Squibb, Celgene, Daiichi-Sankyo, Genentech, Gilead, Jazz, Novartis, Pfizer, Servier, Shattuck Labs, Syndax, Trillium; research support: AbbVie, Amgen, Astellas, Bristol-Myers Squibb, Daiichi-Sankyo, FATE Therapeutics, Genentech, Gilead, Glycomimetics, Hanmi, ImmunoGen, Novimmune, Pfizer, Servier, Trillium, Trovagene; independent contractor: ImmunoGen.